Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab

Abstract

Rituximab is an effective and well-tolerated treatment for patients with ANCA-associated vasculitis and should be strongly considered in severely affected patients who do not respond to standard therapy or in those in whom cytotoxic therapy bears a high risk of morbidity.